Meeting
2014 ASCO Annual Meeting
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Authors
Cariad Chester
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
Cariad Chester , Serena Chang , John F. Kurland , Idit Sagiv-Barfi , Debra Czerwinski , Amanda Rajapaksa , Erin Waller , Mohith Sadaram , Lori Richards , Lewis J. Cohen , Christoph Matthias Ahlers , Maria Jure-Kunkel , Holden Maecker , Ronald Levy , Holbrook Edwin Kohrt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT01471210
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3017)
DOI
10.1200/jco.2014.32.15_suppl.3017
Abstract #
3017
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.
First Author: Gonzalo Tapia
Poster
2022 ASCO Annual Meeting
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
First Author: Jean-Pierre Delord
Poster
2020 ASCO Virtual Scientific Program
A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma.
First Author: Li Zhang
Poster
2020 ASCO Virtual Scientific Program
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
First Author: Alexander Starodub